AC Immune SA (ACIU) - EV/EBITDA Multiple
The market value of the asset on GURU.Markets, which stands at 0.00 as illustrated on this chart, helps assess AC Immune (ACIU), a company integrating environmental standards and bioethics into drug development. The business relies on scientific alliances with pharmaceutical behemoths to combat dementia. Since the company is in the testing phase and lacks a stable cash flow, development is funded through external injections and grants.
Metric breakdowns and analytics for acimmune.com (ACIU)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
ACIU - Net Income|Projected Future Earnings AC Immune|ACIU - Business Payback Period|Projected Price to Earnings AC Immune|ACIU - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AC Immune Inc|ACIU - Operating profit before amortization|Net earnings per share (EPS TTM) AC Immune|ACIU - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months acimmune.com|ACIU - Earnings growth in current year|Net earnings per share growth forecast for next year AC Immune
Fundamental company valuation:AC Immune Corp ACIU
Developing vaccines against Alzheimer's disease requires colossal capital expenditures and long-term financing. By analyzing the EV/EBITDA dynamics, an investor assesses the total enterprise value of AC Immune (ACIU) inclusive of net debt relative to operating profit. This chart reflects the speed of asset payback while preparing for partnerships with pharma behemoths. This allows for a determination of whether the asset is overvalued before the drugs enter the market.
Competitor analysis
Biogen Corp - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation NBIX|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Xenon Pharmaceuticals Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to EBITDA Ratio Supernus Corp (SUPN)|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|EV/EBITDA Multiple denalitherapeutics.com (DNLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|PRAX: EV/EBITDA Multiple|anavex.com (AVXL) - EV/EBITDA Multiple|CBLL (CeriBell) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prothena Corporation PLC (PRTA)|EV/EBITDA Multiple ALEC|Total Company Value to Operating Income Before Depreciation Ratio Annexon Biosciences Inc.|Omeros - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple neurogene.com NGNE|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NMRA (Neumora) - Enterprise Value to Operating Income Before Depreciation|SCLX: EV/EBITDA Multiple|Company Value to EBITDA Tevogen Bio Inc. (TVGN)|Enterprise Value to EBITDA Ratio ACOG|EV/EBITDA Multiple cogrx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|SAVA (Cassava Sciences Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio ASRT|Coya Therapeutics Inc (COYA) - Company Value to EBITDA|VistaGen Therapeutics Inc - EV/EBITDA Multiple|OVID - EV/EBITDA Multiple|ABOS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CervoMed, Inc.|Enterprise Value to EBITDA Ratio ATHE|CLNN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PEPG|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS - Enterprise Value to EBITDA Ratio|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Firefly Neuro (AIFF) - Enterprise Value to EBITDA Ratio|KLTO (anewmeds.com) - Enterprise Value to EBITDA Ratio|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|EV/EBITDA Multiple NRXS|HSDT - Company Value to EBITDA|EV/EBITDA Multiple PASG (Passage Bio)|EV/EBITDA Multiple Neuphoria Therapeutics, Inc. NEUP|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Athira Pharma Inc (ATHA) - Enterprise Value to EBITDA Ratio|ADXN: EV/EBITDA Multiple|ALZN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CYCN|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|cortigent.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BrainStorm Cell Therapeutics Inc. (BCLI) - Company Value to EBITDA|CARA: Enterprise Value to EBITDA Ratio|CHRO - EV/EBITDA Multiple|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Company Value to EBITDA Marinus Pharma MRNS|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|EV/EBITDA Multiple SAGE (Sage Therapeutics)|SNPX - Enterprise Value to EBITDA Ratio|TRVN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|CERE - Total Company Value to Operating Income Before Depreciation Ratio
